Published on in Vol 4, No 2 (2015): Apr-Jun

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Bo Jan Noordman   1 , MD ;   Joel Shapiro   1 , MD ;   Manon CW Spaander   2 , MD,PhD ;   Kausilia K Krishnadath   3 , MD,PhD ;   Hanneke WM van Laarhoven   4 , MD,PhD ;   Mark I van Berge Henegouwen   5 , MD,PhD ;   Grard AP Nieuwenhuijzen   6 , MD,PhD ;   Richard van Hillegersberg   7 , MD,PhD ;   Meindert N Sosef   8 , MD,PhD ;   Ewout W Steyerberg   9 , MD,PhD ;   Bas PL Wijnhoven   1 , MD,PhD ;   J Jan B van Lanschot   1 , MD,PhD

1 Erasmus MC - University Medical Center Rotterdam, Department of Surgery, Rotterdam, Netherlands

2 Erasmus MC - University Medical Center Rotterdam, Department of Gastroenterology, Rotterdam, Netherlands

3 Academic Medical Center, Department of Gastroenterology, Amsterdam, Netherlands

4 Academic Medical Center, Department of Medical Oncology, Amsterdam, Netherlands

5 Academic Medical Center, Department of Surgery, Amsterdam, Netherlands

6 Catharina Cancer Center, Department of Surgery, Eindhoven, Netherlands

7 University Medical Center, Department of Surgery, Utrecht, Netherlands

8 Atrium Medical Center, Department of Surgery, Heerlen, Netherlands

9 Erasmus MC - University Medical Center Rotterdam, Department of Public Health, Rotterdam, Netherlands

Corresponding Author:

  • Bo Jan Noordman, MD
  • Erasmus MC - University Medical Center Rotterdam
  • Department of Surgery
  • Room Z-839
  • s-Gravendijkwal 230
  • Rotterdam
  • Netherlands
  • Phone: 31 107038813
  • Fax: 31 102250647
  • Email: b.noordman@erasmusmc.nl